Celcuity’s gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen’s diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer’s disease, Novo Nordisk’s denecimig demonstrates long-term safety and efficacy in the Phase 3 FRONTIER4 haemophilia A extension study, and Q32 Bio’s bempikibart reports positive Phase 2a results in severe alopecia areata: the most significant clinical trial results 17 July 2026 has to offer from across the pipeline.
This week delivered a notable concentration of data spanning oncology, neurodegenerative disease, rare haematological disorders, and autoimmune dermatology. The standout story is an FDA approval that resolves a two-decade challenge in pathway inhibition, giving oncologists a genuinely new targeted option for one of the most common breast cancer subtypes. The remaining readouts reflect a pipeline that continues to diversify across disease biology, from antisense oligonucleotides targeting a core Alzheimer’s pathology through to engineered antibodies addressing unmet needs in rare bleeding disorders and immune-mediated hair loss. Here, Life Science Daily News brings you the most significant clinical trial results 17 July 2026.
FDA Approves Celcuity’s Gedatolisib as the First Pan-PI3K and mTOR Inhibitor for HR-Positive, HER2-Negative Advanced Breast Cancer
The FDA approved gedatolisib (Revtorpyk) on 14 July 2026 for the treatment of adults with hormone receptor-positive (HR+), HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. Gedatolisib is approved for use in combination with fulvestrant, with or without palbociclib. It is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms and both mTOR complexes (mTORC1 and mTORC2), resolving a challenge that has occupied researchers and drug developers for nearly two decades.
The approval is based on positive results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, an open-label, global, randomised study. The gedatolisib triplet (gedatolisib plus palbociclib and fulvestrant) achieved a median progression-free survival of 9.3 months compared with 2.0 months for fulvestrant alone, corresponding to a 76 per cent reduction in the risk of disease progression or death (HR 0.24; 95% CI: 0.17 to 0.35; p<0.0001). The objective response rate for the triplet was 31.5 per cent versus 1 per cent for fulvestrant, with a median duration of response of 17.5 months. The gedatolisib doublet (gedatolisib plus fulvestrant) also demonstrated a significant benefit, with a median PFS of 7.4 months versus 2.0 months (HR 0.33; 95% CI: 0.24 to 0.48; p<0.0001) and an objective response rate of 28 per cent. The safety profile was consistent with the known effects of comprehensive PI3K/mTOR pathway inhibition, with stomatitis, rash, and hyperglycaemia among the most commonly reported adverse events. Celcuity anticipates commercial launch in late Q3 2026 and plans to submit a supplemental New Drug Application for the PIK3CA-mutated population based on additional VIKTORIA-1 data presented at the 2026 ASCO Annual Meeting.
Biogen’s Diranersen Delivers Phase 2 Proof of Concept as the First Tau-Targeting Therapy to Show Cognitive Benefit in Alzheimer’s Disease
Biogen presented detailed data from the Phase 2 CELIA study on 14 July 2026 at the Alzheimer’s Association International Conference (AAIC) 2026 in London. The study evaluated diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in 416 individuals with early Alzheimer’s disease. Diranersen is the first tau-directed therapy to demonstrate both robust reductions in cerebrospinal fluid total tau (mean reductions of 50 to 65 per cent) and brain tau pathology as measured by PET imaging, alongside cognitive benefit, in a Phase 2 study. The therapy was discovered by Ionis Pharmaceuticals and has received FDA Fast Track designation.
The 60 mg dose administered intrathecally every six months showed the strongest clinical response at 18 months. Compared with placebo, diranersen 60 mg demonstrated a 26 per cent slowing of clinical decline on CDR-SB, 42 per cent on ADAS-Cog13, and 50 per cent on MMSE, with the majority of these differences achieving nominal statistical significance. Clinical effects were also observed at the two higher dose regimens (115 mg every six months and 115 mg every three months), although higher doses were not associated with greater benefit. The study did not meet its prespecified primary endpoint of dose response on CDR-SB, but the consistency of efficacy signals across multiple cognitive endpoints and the strength of the biomarker data have led Biogen to advance diranersen into confirmatory Phase 3 development. Diranersen was generally well tolerated, with most adverse events mild or moderate in severity. More than 90 per cent of participants who completed the placebo-controlled period elected to continue into the extension study.
Novo Nordisk’s Denecimig Shows Sustained Efficacy and Safety in Phase 3 FRONTIER4 Haemophilia A Extension Study
Novo Nordisk presented interim data from the Phase 3 FRONTIER4 extension study on 11 July 2026 at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Paris. The open-label study included 426 people with haemophilia A aged one year and older receiving denecimig (Mim8) prophylaxis across once-weekly, once-every-two-weeks, and once-monthly dosing. Denecimig is an investigational bispecific antibody that mimics the function of activated Factor VIII, designed as a subcutaneous prophylactic treatment for people with haemophilia A with or without inhibitors. Novo Nordisk submitted a Biologics License Application to the FDA in September 2025.
The safety profile was consistent with findings previously reported across the FRONTIER programme. Injection site reactions were reported at low rates (2.0 per cent of injections in children and 1.8 per cent in adolescents and adults), all mild and transient, with no clinical evidence of neutralising antibodies. Estimated mean annualised bleeding rates were 0.75 (95% CI: 0.60 to 0.93) for adults and adolescents and 0.37 (95% CI: 0.17 to 0.76) for children, consistent with findings from the pivotal trials. Across all doses, approximately 71 per cent of adults and adolescents and 89 per cent of children experienced zero treated bleeds. Patient-reported outcomes showed maintained improvements in joint pain and reduced treatment burden, and 94.1 per cent of participants found the denecimig pen-injector easy or very easy to use. Separate post hoc analyses demonstrated that denecimig prophylaxis increased thrombin generation into the normal reference range without excessive response, further supporting the drug’s clinical profile.
Q32 Bio’s Bempikibart Demonstrates Robust Hair Regrowth and Favourable Safety in Phase 2a Alopecia Areata Trial
Q32 Bio announced positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial on 13 July 2026, evaluating bempikibart in 33 patients with severe or very severe alopecia areata, including those previously treated with JAK inhibitors. Bempikibart is a fully human anti-IL-7 receptor alpha antibody designed to re-regulate adaptive immune function and address the root cause of hair follicle destruction. The company plans to advance a registration-directed programme in the first half of 2027.
The study met its primary efficacy endpoint, demonstrating a 35.3 per cent mean reduction in SALT (Severity of Alopecia Tool) score from baseline at week 36 in the modified intent-to-treat population. Responses were observed in patients with both severe and very severe disease. Forty per cent of patients achieved a SALT-20 response (a SALT score of 20 or below, indicating at least 80 per cent scalp hair coverage), and 44 per cent reached SALT-30 and SALT-50, outcomes the company described as comparing favourably with existing therapies in this severity bracket. One patient achieved complete hair regrowth, and early signs of durable off-drug responses were observed in patients who had maintained hair growth at entry. Bempikibart was well tolerated, with no treatment-related serious adverse events and no Grade 3 or higher events reported. The most common adverse events were mild and transient injection site reactions. Pharmacokinetic and anti-drug antibody profiles were favourable, with negligible immunogenicity observed.
Looking Ahead
This week’s clinical trial results 17 July 2026 span some of the most consequential areas of the current pharmaceutical pipeline. Gedatolisib’s approval as the first comprehensive PI3K/mTOR inhibitor gives oncologists a practice-changing new option for one of breast cancer’s most common molecular subtypes. The CELIA data for diranersen mark a potentially pivotal moment in Alzheimer’s disease research, providing the first Phase 2 evidence that targeting tau can translate into measurable cognitive benefit. In haemophilia, the FRONTIER4 extension data reinforce the consistency and durability of denecimig’s clinical profile as it moves through regulatory review. And in autoimmune dermatology, bempikibart’s encouraging efficacy and safety in severe alopecia areata position it as a credible alternative to JAK inhibitors for patients who need a targeted, durable treatment option. Life Science Daily News will continue to bring you comprehensive, timely coverage of the clinical trial results 17 July 2026 that matter most to patients, clinicians, and the broader life science community.
This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently.
